Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
Fox Chase Cancer Center
Summary
This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection.
Description
This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection. The concomitant use of radiation and immunotherapy as part of the neoadjuvant protocol is allowed in this protocol. The study is designed to evaluate the efficacy of iron infusions in reducing blood transfusion frequency and improving hemoglobin levels prior to surgical intervention.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female patients \> 18 years * Patients undergoing neoadjuvant chemotherapy, including radiation and/or immunotherapy, with intent for curative surgical resection for breast, thoracic, gastrointestinal (GI) or genitourinary (GU) malignancies. * Anemia defined as Hgb \<10.5 g/dL during chemotherapy. * Iron storage levels of ferritin \<500 ng/mL and iron saturation \<35% * Ability to understand and willingness to sign a written informed consent and HIPAA consent document Exclusion Criteria: * Diagnosis of anemia at the time of cycle 1 day 1 of neoadjuvant chemothe…
Interventions
- DrugVenofer
Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
Location
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania